| OTC Markets: PYMXQ
PolyMedix, Inc. is a clinical stage biotechnology company. It develops first-in-class, small-molecule defensin-mimetics for the treatment of serious acute care conditions. The company's infectious disease drug candidate is PMX-30063, the first of a new class of antibiotics, the defensin-mimetics, which imitates the natural human immunity and exploits a method of bacterial cell killing which should significantly reduce the risk of bacterial resistance. Its PMX-30063 has completed a Phase 2 clinical trial in patients with acute bacterial skin and skin structure infections caused by Staph aureus bacteria, including methicillin-resistant staph aureus. PolyMedix was founded in 2002 and is headquartered in Radnor, PA.